These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
104 related articles for article (PubMed ID: 10525455)
1. DNA-based vaccination against tumors expressing the P1A antigen. Rosato A; Milan G; Collavo D; Zanovello P Methods; 1999 Sep; 19(1):187-90. PubMed ID: 10525455 [TBL] [Abstract][Full Text] [Related]
2. Vaccination with recombinant adenoviruses and dendritic cells expressing prostate-specific antigens is effective in eliciting CTL and suppresses tumor growth in the experimental prostate cancer. Kim S; Lee JB; Lee GK; Chang J Prostate; 2009 Jun; 69(9):938-48. PubMed ID: 19267351 [TBL] [Abstract][Full Text] [Related]
3. DNA vaccination against tumors. Prud'homme GJ J Gene Med; 2005 Jan; 7(1):3-17. PubMed ID: 15538731 [TBL] [Abstract][Full Text] [Related]
4. Vaccine therapy of established tumors in the absence of autoimmunity. Hodge JW; Grosenbach DW; Aarts WM; Poole DJ; Schlom J Clin Cancer Res; 2003 May; 9(5):1837-49. PubMed ID: 12738742 [TBL] [Abstract][Full Text] [Related]
5. Plasmid DNA vaccines against cancer: cytotoxic T-lymphocyte induction against tumor antigens. Pavlenko M; Leder C; Pisa P Expert Rev Vaccines; 2005 Jun; 4(3):315-27. PubMed ID: 16026247 [TBL] [Abstract][Full Text] [Related]
6. The boosting effect of co-transduction with cytokine genes on cancer vaccine therapy using genetically modified dendritic cells expressing tumor-associated antigen. Ojima T; Iwahashi M; Nakamura M; Matsuda K; Naka T; Nakamori M; Ueda K; Ishida K; Yamaue H Int J Oncol; 2006 Apr; 28(4):947-53. PubMed ID: 16525645 [TBL] [Abstract][Full Text] [Related]
7. Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice. Zhang X; Yu C; Zhao J; Fu L; Yi S; Liu S; Yu T; Chen W J Gene Med; 2007 Aug; 9(8):715-26. PubMed ID: 17595048 [TBL] [Abstract][Full Text] [Related]
8. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control. Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230 [TBL] [Abstract][Full Text] [Related]
10. Specific antitumor immune response induced by a novel DNA vaccine composed of multiple CTL and T helper cell epitopes of prostate cancer associated antigens. Qin H; Zhou C; Wang D; Ma W; Liang X; Lin C; Zhang Y; Zhang S Immunol Lett; 2005 Jun; 99(1):85-93. PubMed ID: 15894116 [TBL] [Abstract][Full Text] [Related]
11. Gene gun-mediated DNA vaccination induces antitumor immunity against human papillomavirus type 16 E7-expressing murine tumor metastases in the liver and lungs. Chen CH; Ji H; Suh KW; Choti MA; Pardoll DM; Wu TC Gene Ther; 1999 Dec; 6(12):1972-81. PubMed ID: 10637448 [TBL] [Abstract][Full Text] [Related]
12. Individual analysis of mice vaccinated against a weakly immunogenic self tumor-specific antigen reveals a correlation between CD8 T cell response and antitumor efficacy. Rosato A; Zoso A; Milan G; Macino B; Dalla Santa S; Tosello V; Di Carlo E; Musiani P; Whalen RG; Zanovello P J Immunol; 2003 Nov; 171(10):5172-9. PubMed ID: 14607917 [TBL] [Abstract][Full Text] [Related]
13. In vivo effects of vaccination with six-transmembrane epithelial antigen of the prostate: a candidate antigen for treating prostate cancer. Garcia-Hernandez Mde L; Gray A; Hubby B; Kast WM Cancer Res; 2007 Feb; 67(3):1344-51. PubMed ID: 17283172 [TBL] [Abstract][Full Text] [Related]
14. A MUC1/IL-18 DNA vaccine induces anti-tumor immunity and increased survival in MUC1 transgenic mice. Snyder LA; Goletz TJ; Gunn GR; Shi FF; Harris MC; Cochlin K; McCauley C; McCarthy SG; Branigan PJ; Knight DM Vaccine; 2006 Apr; 24(16):3340-52. PubMed ID: 16472547 [TBL] [Abstract][Full Text] [Related]
15. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Colmenero P; Liljeström P; Jondal M Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722 [TBL] [Abstract][Full Text] [Related]
16. Immuno-viral therapy of brain tumors by combination of viral therapy with cancer vaccination using a replication-conditional HSV. Toda M; Iizuka Y; Kawase T; Uyemura K; Kawakami Y Cancer Gene Ther; 2002 Apr; 9(4):356-64. PubMed ID: 11960286 [TBL] [Abstract][Full Text] [Related]
17. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449 [TBL] [Abstract][Full Text] [Related]
18. Intra-pinna anti-tumor vaccination with self-replicating infectious RNA or with DNA encoding a model tumor antigen and a cytokine. Schirmacher V; Förg P; Dalemans W; Chlichlia K; Zeng Y; Fournier P; von Hoegen P Gene Ther; 2000 Jul; 7(13):1137-47. PubMed ID: 10918481 [TBL] [Abstract][Full Text] [Related]
19. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model. Tillman BW; Hayes TL; DeGruijl TD; Douglas JT; Curiel DT Cancer Res; 2000 Oct; 60(19):5456-63. PubMed ID: 11034088 [TBL] [Abstract][Full Text] [Related]
20. Immunostimulatory DNA-based vaccines induce cytotoxic lymphocyte activity by a T-helper cell-independent mechanism. Cho HJ; Takabayashi K; Cheng PM; Nguyen MD; Corr M; Tuck S; Raz E Nat Biotechnol; 2000 May; 18(5):509-14. PubMed ID: 10802617 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]